Literature DB >> 21362139

Tec family kinases Itk and Rlk / Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates.

Julio Gomez-Rodriguez1, Zachary J Kraus, Pamela L Schwartzberg.   

Abstract

Developing thymocytes and T cells express the Tec kinases Itk, Rlk/Txk and Tec, which are critical modulators of T-cell receptor signaling, required for full activation of phospholipase Cγ, and downstream Ca(2+) and ERK-mediated signaling pathways. Over the last 10 years, data have implicated the Tec family kinases Itk and Rlk/Txk as important regulators of cytokine production by CD4(+) effector T-cell populations. Emerging data now suggest that the Tec family kinases not only influence cytokine-producing T-cell populations in the periphery, but also regulate the development of distinct innate-type cytokine-producing T-cell populations in the thymus. Together, these results suggest that the Tec family kinases play critical roles in helping shape immune responses via their effects on the differentiation and function of distinct cytokine-producing, effector T-cell populations. Journal compilation
© 2011 FEBS. No claim to original US government works.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21362139      PMCID: PMC3117960          DOI: 10.1111/j.1742-4658.2011.08072.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  45 in total

1.  NK T cell precursors exhibit differential cytokine regulation and require Itk for efficient maturation.

Authors:  Paul Gadue; Paul L Stein
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

2.  Signaling through Itk promotes T helper 2 differentiation via negative regulation of T-bet.

Authors:  Andrew T Miller; Heather M Wilcox; Zhongbin Lai; Leslie J Berg
Journal:  Immunity       Date:  2004-07       Impact factor: 31.745

3.  Expression and function of Tec, Itk, and Btk in lymphocytes: evidence for a unique role for Tec.

Authors:  Michael G Tomlinson; Lawrence P Kane; Jennifer Su; Theresa A Kadlecek; Marianne N Mollenauer; Arthur Weiss
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

4.  ITK and IL-15 support two distinct subsets of CD8+ T cells.

Authors:  Sigrid Dubois; Thomas A Waldmann; Jürgen R Müller
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-31       Impact factor: 11.205

Review 5.  SLAM receptors and SAP influence lymphocyte interactions, development and function.

Authors:  Pamela L Schwartzberg; Kristen L Mueller; Hai Qi; Jennifer L Cannons
Journal:  Nat Rev Immunol       Date:  2009-01       Impact factor: 53.106

6.  Attenuation of immunological symptoms of allergic asthma in mice lacking the tyrosine kinase ITK.

Authors:  Cynthia Mueller; Avery August
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

7.  The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions.

Authors:  Damian Kovalovsky; Olisambu U Uche; Sonia Eladad; Robin M Hobbs; Woelsung Yi; Eric Alonzo; Kevin Chua; Maggie Eidson; Hye-Jung Kim; Jin S Im; Pier Paolo Pandolfi; Derek B Sant'Angelo
Journal:  Nat Immunol       Date:  2008-07-27       Impact factor: 25.606

8.  Selective expression rather than specific function of Txk and Itk regulate Th1 and Th2 responses.

Authors:  Nisebita Sahu; Ana M Venegas; Dragana Jankovic; Wayne Mitzner; Julio Gomez-Rodriguez; Jennifer L Cannons; Connie Sommers; Paul Love; Alan Sher; Pamela L Schwartzberg; Avery August
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

9.  The transcriptional regulator PLZF induces the development of CD44 high memory phenotype T cells.

Authors:  Julia Raberger; Alexandra Schebesta; Shinya Sakaguchi; Nicole Boucheron; K Emelie M Blomberg; Anna Berglöf; Thomas Kolbe; C I Edvard Smith; Thomas Rülicke; Wilfried Ellmeier
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-12       Impact factor: 11.205

10.  The transcription factor PLZF directs the effector program of the NKT cell lineage.

Authors:  Adam K Savage; Michael G Constantinides; Jin Han; Damien Picard; Emmanuel Martin; Bofeng Li; Olivier Lantz; Albert Bendelac
Journal:  Immunity       Date:  2008-08-14       Impact factor: 31.745

View more
  28 in total

1.  IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma.

Authors:  Craig C Carson; Stergios J Moschos; Sharon N Edmiston; David B Darr; Nana Nikolaishvili-Feinberg; Pamela A Groben; Xin Zhou; Pei Fen Kuan; Shaily Pandey; Keefe T Chan; Jamie L Jordan; Honglin Hao; Jill S Frank; Dennis A Hopkinson; David C Gibbs; Virginia D Alldredge; Eloise Parrish; Sara C Hanna; Paula Berkowitz; David S Rubenstein; C Ryan Miller; James E Bear; David W Ollila; Norman E Sharpless; Kathleen Conway; Nancy E Thomas
Journal:  Clin Cancer Res       Date:  2015-05-01       Impact factor: 12.531

2.  Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects.

Authors:  H Yesid Estupiñán; Thibault Bouderlique; Chenfei He; Anna Berglöf; Dhanu Gupta; Osama Saher; Miguel Ángel Daza Cruz; Lucia Peña-Perez; Liang Yu; Rula Zain; Mikael C I Karlsson; Robert Månsson; C I Edvard Smith
Journal:  Blood Adv       Date:  2020-06-09

Review 3.  Back to the future: oral targeted therapy for RA and other autoimmune diseases.

Authors:  John J O'Shea; Arian Laurence; Iain B McInnes
Journal:  Nat Rev Rheumatol       Date:  2013-02-19       Impact factor: 20.543

4.  Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

Authors:  Jason A Dubovsky; Ryan Flynn; Jing Du; Bonnie K Harrington; Yiming Zhong; Benjamin Kaffenberger; Carrie Yang; William H Towns; Amy Lehman; Amy J Johnson; Natarajan Muthusamy; Steven M Devine; Samantha Jaglowski; Jonathan S Serody; William J Murphy; David H Munn; Leo Luznik; Geoffrey R Hill; Henry K Wong; Kelli K P MacDonald; Ivan Maillard; John Koreth; Laurence Elias; Corey Cutler; Robert J Soiffer; Joseph H Antin; Jerome Ritz; Angela Panoskaltsis-Mortari; John C Byrd; Bruce R Blazar
Journal:  J Clin Invest       Date:  2014-10-01       Impact factor: 14.808

5.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Authors:  Jason A Dubovsky; Kyle A Beckwith; Gayathri Natarajan; Jennifer A Woyach; Samantha Jaglowski; Yiming Zhong; Joshua D Hessler; Ta-Ming Liu; Betty Y Chang; Karilyn M Larkin; Matthew R Stefanovski; Danielle L Chappell; Frank W Frissora; Lisa L Smith; Kelly A Smucker; Joseph M Flynn; Jeffrey A Jones; Leslie A Andritsos; Kami Maddocks; Amy M Lehman; Richard Furman; Jeff Sharman; Anjali Mishra; Michael A Caligiuri; Abhay R Satoskar; Joseph J Buggy; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2013-07-25       Impact factor: 22.113

6.  Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.

Authors:  Zheng Zhao; Qingsong Liu; Spencer Bliven; Lei Xie; Philip E Bourne
Journal:  J Med Chem       Date:  2017-04-04       Impact factor: 7.446

7.  Allele-sensitive mutant, Itkas, reveals that Itk kinase activity is required for Th1, Th2, Th17, and iNKT-cell cytokine production.

Authors:  Arun Kannan; YongChan Lee; Qian Qi; Weishan Huang; Ah-Reum Jeong; Sarah Ohnigian; Avery August
Journal:  Eur J Immunol       Date:  2015-06-10       Impact factor: 5.532

8.  The DEL-1/β3 integrin axis promotes regulatory T cell responses during inflammation resolution.

Authors:  Xiaofei Li; Alessandra Colamatteo; Lydia Kalafati; Tetsuhiro Kajikawa; Hui Wang; Jong-Hyung Lim; Khalil Bdeir; Kyoung-Jin Chung; Xiang Yu; Clorinda Fusco; Antonio Porcellini; Salvatore De Simone; Giuseppe Matarese; Triantafyllos Chavakis; Veronica De Rosa; George Hajishengallis
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

Review 9.  How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.

Authors:  Samantha M Jaglowski; Bruce R Blazar
Journal:  Blood Adv       Date:  2018-08-14

10.  TEC and MAPK Kinase Signalling Pathways in T helper (TH) cell Development, TH2 Differentiation and Allergic Asthma.

Authors:  Yashaswini Kannan; Mark S Wilson
Journal:  J Clin Cell Immunol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.